0001209191-23-006881.txt : 20230203 0001209191-23-006881.hdr.sgml : 20230203 20230203163255 ACCESSION NUMBER: 0001209191-23-006881 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230201 FILED AS OF DATE: 20230203 DATE AS OF CHANGE: 20230203 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Patel Priti CENTRAL INDEX KEY: 0001859997 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36327 FILM NUMBER: 23586520 MAIL ADDRESS: STREET 1: C/O NEOLEUKIN THERAPEUTICS, INC. STREET 2: 188 EAST BLAINE STREET, #450 CITY: SEATTLE STATE: WA ZIP: 98102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Neoleukin Therapeutics, Inc. CENTRAL INDEX KEY: 0001404644 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: SUITE 360 - 1616 EASTLAKE AVE EAST CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-732-2133 MAIL ADDRESS: STREET 1: SUITE 360 - 1616 EASTLAKE AVE EAST CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: AQUINOX PHARMACEUTICALS, INC DATE OF NAME CHANGE: 20140128 FORMER COMPANY: FORMER CONFORMED NAME: AQUINOX PHARMACEUTICALS (USA) INC DATE OF NAME CHANGE: 20070626 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-01 0 0001404644 Neoleukin Therapeutics, Inc. NLTX 0001859997 Patel Priti C/O NEOLEUKIN THERAPEUTICS, INC. 188 EAST BLAINE STREET, #450 SEATTLE WA 98102 0 1 0 0 Chief Medical Officer Common Stock 2023-02-01 4 M 0 35000 0.00 A 45462 D Common Stock 2023-02-02 4 S 0 14380 0.5972 D 31082 D Restricted Stock Units 0.00 2023-02-01 4 M 0 35000 0.00 D Common Stock 35000 35000 D Includes 2,000 shares of Common Stock acquired by the Reporting Person on May 13, 2022 and 2,000 shares of Common Stock acquired by the Reporting Person on November 15, 2022 pursuant to the Issuer's employee stock purchase plan. The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Represents the weighted average sale price. The lowest price at which shares were sold was $0.576 and the highest price at which shares were sold was $0.635. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth herein. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. The RSUs will vest as to 1/2 of the total number of shares underlying the award on each of February 1, 2023 and February 1, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The RSUs do not expire; these securities either vest and settle or are canceled prior to the vesting date. /s/ Sean Smith, Attorney-in-Fact for Priti Patel 2023-02-03